We are a consumer driven, pharma company, devoted to research and development of beneficial products based on our novel Buccal Extended Release Drug Delivery System.
Lasting Effect developed a buccal adhesive tablet for dry mouth (xerostomia) treatment and continuous oral health. The tablet intended for stimulating salivation.
The tablet contains flavors and active ingredients, all known for their saliva stimulation effect.
After extensive testing for the API that gives the best results, Lasting Effect developed an anti-inflammatory and antibacterial API. We successfully in vitro tested our tablet on Gingivitis causing bacteria. Our buccal tablet inhibited 93-96% of Gingival bacteria.
Parkinson’s symptoms arise from dopamine declines and affect patients in late stage of Parkinson disease.
The current solution for late-stage Parkinson motor complications: An invasive device/pump for continuous and prolonged delivery of L-DOPA and Carbidopa to a Parkinson’s patient with the goal to receive continuous dopaminergic stimulation.
Our solution: Buccal extended-release tablet loaded with our researched API for continuous dopamine secretion.
